96948-64-0

Usage

Uses

Used in Pharmaceutical Industry:
Kwd 2066 is used as a pharmaceutical agent for its potential effects on the adrenergic and dopaminergic systems. Its interaction with β-adrenergic receptors and β-adrenergic receptor-coupled adenylate cyclase suggests potential therapeutic applications in treating various conditions related to these systems.
Used in Research Applications:
Kwd 2066 is used as a research tool for studying the structure-activity relationship of β-adrenergic receptors and their associated signaling pathways. This can help in understanding the mechanisms of action of various drugs and developing new therapeutic agents targeting these receptors.

InChI:InChI=1/C12H19NO2/c1-12(2,3)13-8-11(15)9-4-6-10(14)7-5-9/h4-7,11,13-15H,8H2,1-3H3

Upstream product

• 4254-67-5 2-bromo-1-(4-benzyloxyphenyl)-1-ethanone 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 5324-15-2 4'-benzoyloxy-2-bromoacetophenone 
• 60853-18-1 2-tert-butylamino-1-(4-hydroxy-phenyl)-ethanone 

Downstream Products

• 93739-47-0 VUF 8303 

Relevant academic research and scientific papers

BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

Identification of Buctopamine and Mebuctopamine, a β2 Receptor Agonist and Its Metabolite, in Swine Hair and Feed Additives

4-[2-(t-Butylamino)-1-hydroxyethyl]phenol (buctopamine, 4), a new β2 receptor agonist (β2-agonist), was found to be an adulterant in feed additives for swine in Taiwan, where using β2-agonists in food-production animals is

COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, such as type 2 diabetes, wherein X, R1, R2, R3 and n have meanings as provided in the description.